Methotrexate Accord Healthcare (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate. This cofactor is essential for synthesizing purines and pyrimidines, the building blocks of DNA and RNA. By limiting these nucleotides, methotrexate hampers the growth of rapidly dividing cells, including malignant cells and activated immune cells.

The dose of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Dosing regimens can vary widely, ranging from low weekly doses for autoimmune disease to higher, more frequent doses for oncologic protocols.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided due to potential infant exposure through milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is often considered a first‑line disease‑modifying antirheumatic drug (DMARD) because of its proven efficacy, oral and injectable formulations, and cost‑effectiveness. Compared with biologic agents, it has a broader safety profile but may require more laboratory monitoring. Its mechanism differs from biologics, which target specific cytokines or cell surface receptors.

Methotrexate Accord Healthcare should be stored at ambient temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing. Ensure the storage area is dry and well‑ventilated to maintain product stability.

Methotrexate is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intravenous routes, depending on the clinical indication and dosing schedule. Administration is performed by qualified healthcare professionals under aseptic conditions, with dosage intervals typically ranging from weekly to daily in oncologic protocols.

The most serious risks include bone marrow suppression leading to severe cytopenias, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening anaphylactic reactions. Patients should be monitored regularly for laboratory abnormalities and clinical signs of toxicity.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active infections, and in women who are pregnant or planning pregnancy without effective contraception. Caution is also advised for individuals with pre‑existing blood dyscrasias or pulmonary disease.